A substantial proportion of people who experience type 2 diabetes remission after gastric bypass eventually have relapse of the disease down the road. I feel the best study of this was done by my co-author on CROSSROADS, David Arterburn. In a study of nearly 5,000 patients with diabetes who underwent [gastric bypass surgery] and were followed retrospectively for 13 years, about 70% experienced diabetes remission. Among these, about 1/3 eventually relapsed, but it’s important to note that the median disease-free interval was 8.3 years.
It was the same endorsement the first Diabetes Surgery Summit, also organized by Cummings in 2007, had made, but the landscape had changed since then. In addition to more accumulated research, this time, their stance was backed by over 50 international professional organizations, including the American Diabetes Association. And while other medical societies and organizations had long backed surgery as an option for diabetes, the DSS-II guidelines are the first meant to guide clinical practice.
This event goes well beyond the initial vision of Wanderlust’s CEO, Sean Hoess, who sat down with me one morning by a hotel pool in running clothes. Hoess is 48, but like many Wellspring attendees looks a decade younger. He just renovated a house in Greenpoint, Brooklyn, and is openly “not a wellness buff”—he prefers tennis. After graduating from Columbia University, he went to law school, but quit practicing to start a record label with a college friend, Jeff Krasno. Krasno’s wife, Schuyler Grant, ran a yoga studio above their office, and the three of them had the idea to start a festival combining the two fields.
Type 2 diabetes, a form of diabetes mellitus, is likely one of the better-known chronic diseases in the world — and that's no surprise. Data from the Centers for Disease Control and Prevention suggest in the United States alone, 30.3 million people, or 9.4 percent of the U.S. population, has diabetes, and the majority of these people have type 2. (1)
People with diabetes may also worry about trying new foods; traveling; diabetes complications; the toll the condition takes on their family; and healthcare costs, which are 2.3 times higher than for someone without diabetes. For Sandi, she worries about the cost of medication and, if her kidneys worsen, the possibility that she’ll have to go on dialysis. “That’s a really scary thought,” she says.
Darkes said several medical professionals worked with him when he was in St. Louis, but he could name only his senior consultant, Dr. Michael Berk. Berk is an endocrinologist who runs his own practice in St. Louis and is also a clinical associate at Washington University. Because Darkes declined a request to submit a medical release form to Berk's office, Live Science could not confirm key elements of his story, or whether or not he was even a patient of Dr. Berk.
The bionic pancreas is another project from Boston University and Massachusetts General Hospital in a joint effort to create a bionic pancreas, a type of artificial pancreas which not only includes insulin but also glucagon to raise blood sugar. The system is intended to use an algorithm that checks every 5 minutes to calculate the amount of insulin or glucagon needed. The project has recently formed into a public benefit corporation called Beta Bionics. This newer structure allows it to serve not just shareholders, but also the public good. Beta Bionics also became the first American company to raise over a $1 million from small investors under new public investing rules!
There are some interesting developments in blood glucose monitoring including continuous glucose sensors. The new continuous glucose sensor systems involve an implantable cannula placed just under the skin in the abdomen or in the arm. This cannula allows for frequent sampling of blood glucose levels. Attached to this is a transmitter that sends the data to a pager-like device. This device has a visual screen that allows the wearer to see, not only the current glucose reading, but also the graphic trends. In some devices, the rate of change of blood sugar is also shown. There are alarms for low and high sugar levels. Certain models will alarm if the rate of change indicates the wearer is at risk for dropping or rising blood glucose too rapidly. One version is specifically designed to interface with their insulin pumps. In most cases the patient still must manually approve any insulin dose (the pump cannot blindly respond to the glucose information it receives, it can only give a calculated suggestion as to whether the wearer should give insulin, and if so, how much). However, in 2013 the US FDA approved the first artificial pancreas type device, meaning an implanted sensor and pump combination that stops insulin delivery when glucose levels reach a certain low point. All of these devices need to be correlated to fingersticks measurements for a few hours before they can function independently. The devices can then provide readings for 3 to 5 days.
That is the goal of Imcyse, a French company running a clinical trial with an immunotherapy designed to stop type 1 diabetes. Patients that have been diagnosed within the last 6 months, who still retain some insulin-producing cells, are given a treatment designed to make the immune system destroy the specific immune cells that are attacking insulin-producing cells. Results are expected later this year and will reveal whether the treatment has the potential to become a cure.
In this diabetes-related complication, an uncooperative stomach is slow to move food into the intestine, and does so unpredictably. The symptoms of gastroparesis include upper abdominal pain, nausea, vomiting, bloating, lack of appetite, and reflux, the flowing backward of stomach contents into the esophagus. Wild, unexplained swings in blood glucose are another clue that you may have gastroparesis. For example, blood glucose may go low if food isn’t absorbed until after mealtime insulin takes effect; later, blood glucose levels may spike, when the stomach finally ushers food into the intestine and there’s not enough remaining insulin on board.
According to Christine Sullivan, founder of Real Help for Chronic Pain, an online pain management program, “Chronic pain is almost never merely a physical thing. We can see from brain mapping that chronic pain uses very different nerve paths from acute pain. In fact, the brain maps of chronic pain look just like the brain maps of intense emotions like anger, or sadness, or fear.”
At present, the American Diabetes Association does not recommend general screening of the population for type 1 diabetes, though screening of high risk individuals, such as those with a first degree relative (sibling or parent) with type 1 diabetes should be encouraged. Type 1 diabetes tends to occur in young, lean individuals, usually before 30 years of age; however, older patients do present with this form of diabetes on occasion. This subgroup is referred to as latent autoimmune diabetes in adults (LADA). LADA is a slow, progressive form of type 1 diabetes. Of all the people with diabetes, only approximately 10% have type 1 diabetes and the remaining 90% have type 2 diabetes.
When you have type 2 diabetes, your cells don't get enough glucose, which may cause you to lose weight. Also, if you are urinating more frequently because of uncontrolled diabetes, you may lose more calories and water, resulting in weight loss, says Daniel Einhorn, MD, medical director of the Scripps Whittier Diabetes Institute and clinical professor of medicine at the University of California in San Diego.
But carping over wellness faded away in the ’90s as the term gained a foothold in everyday use. The American Heritage Dictionary silently dropped the usage note on wellness in its fourth edition in 2000, a decision that its supervising editor, Steve Kleinedler, chalks up to the growing prevalence of wellness programs in the workplace and beyond. A word that once sounded strange and unnecessary, even to its original boosters, has become tacitly accepted as part of our lexicon of health. Well, well, well.
For a wellness festival, there was an unexpected amount of talk about the importance of suffering and pain. In one panel about addiction, the ultramarathoner Charlie Engle, who ran 30 marathons in his first three years of sobriety, told the story of his first son being born. “He was gonna save me,” Engle recalled, “and then six days later, after a crack binge, the police are searching my car, and I had to choose between living and dying. And I chose running ... I wanted to pound that part of me out and never visit it again.”
But early last year, routine finger-prick tests showed his blood-sugar levels were normal, so doctors advised him to stop his insulin injections, Darkes said. Now, his doctors have told him they're 80 percent sure he's cured, the Northampton Chronicle and Echo reported. If true, this would mean Darkes could be the first person ever to naturally experience complete remission of type 1 diabetes. [27 Oddest Medical Cases]
“The cell is the original smart machine,” notes Crystal Nyitray, PhD, on the website of Encellin, the biotech start-up she founded in 2016. “All drugs, devices, and even digital health approaches are trying to restore or copy these functions. At Encellin, we believe in the human cell and creating a safe and reliable solution for patients. We are creating a technology to promote cell function and protection.”
Founded in 2007, San Francisco startup NGM Biopharmaceuticals is a pharmaceutical company that has raised $295.4 million, with pharmaceutical giant Merck & Co., as one of its most recent investors. The company has just filed to sell $75 million of its common stock in an IPO. The company’s primary candidate for treating diabetes is NGM313, an engineered antibody that binds to a novel pathway that reduces insulin resistance. After the successful conclusion of a phase I on the drug, NGM plans to license the antibody to Merck.
The earliest surviving work with a detailed reference to diabetes is that of Aretaeus of Cappadocia (2nd or early 3rd century CE). He described the symptoms and the course of the disease, which he attributed to the moisture and coldness, reflecting the beliefs of the "Pneumatic School". He hypothesized a correlation of diabetes with other diseases, and he discussed differential diagnosis from the snakebite which also provokes excessive thirst. His work remained unknown in the West until 1552, when the first Latin edition was published in Venice.
Dunn collected his presentations in a 1961 book, “High-Level Wellness,” but it would take another decade for his work to resonate with a committed group of followers. An early acolyte was John W. Travis, who picked up Dunn’s book in 1972 from a $2 clearance table at the bookstore of Johns Hopkins Medical School, where he was enrolled in a preventive-medicine residency program. Travis didn’t think much of Dunn’s buzzword at first. “I thought the word wellness was stupid, and it would never catch on,” he recently told me. But Travis was enamored with the way Dunn presented his ideas, and he put those ideas into action — and reluctantly embraced the word itself — when he opened the Wellness Resource Center in Mill Valley, Calif., in November 1975. The center promoted self-directed approaches to well-being as an alternative to the traditional illness-oriented care of physicians.
Diabetes is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose comes from the foods you eat. Insulin is a hormone that helps the glucose get into your cells to give them energy. With type 1 diabetes, your body does not make insulin. With type 2 diabetes, the more common type, your body does not make or use insulin well. Without enough insulin, the glucose stays in your blood. You can also have prediabetes. This means that your blood sugar is higher than normal but not high enough to be called diabetes. Having prediabetes puts you at a higher risk of getting type 2 diabetes.